Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

Consensus Europe Humans Immunotherapy, Adoptive / methods Multiple Myeloma / therapy Practice Guidelines as Topic / standards Societies, Medical

Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
12 2019
Historique:
received: 24 04 2019
accepted: 21 08 2019
pubmed: 24 8 2019
medline: 5 8 2020
entrez: 24 8 2019
Statut: ppublish

Résumé

Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved in relapsed/refractory MM, it will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in MM, and discusses several important issues for its future development.

Identifiants

DOI: 10.3324/haematol.2019.224204 PMID: 31439675 PMC: PMC6959167
pubmed: 31439675
pii: haematol.2019.224204
doi: 10.3324/haematol.2019.224204
pmc: PMC6959167
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2358-2360

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright© 2019 Ferrata Storti Foundation.

Références

Front Oncol. 2019 Mar 12;9:146
pubmed: 30915277
Blood. 2017 Dec 14;130(24):2594-2602
pubmed: 28928126
Blood. 2016 Sep 29;128(13):1688-700
pubmed: 27412889
Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326
pubmed: 30810049
Clin Adv Hematol Oncol. 2018 Dec;16(12):804-806
pubmed: 30843888
EMBO J. 1992 Nov;11(11):3897-904
pubmed: 1396583
Ther Adv Hematol. 2019 Jan 18;10:2040620718822660
pubmed: 30719268
J Hematol Oncol. 2018 Dec 20;11(1):141
pubmed: 30572922
Nature. 2019 Apr;568(7750):112-116
pubmed: 30918399
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825

Auteurs

Philippe Moreau (P)

University Hospital Hôtel-Dieu, Nantes, France philippe.moreau@chu-nantes.fr.

Pieter Sonneveld (P)

Erasmus Medical Center, Rotterdam, the Netherlands.

Mario Boccadoro (M)

Università di Torino/Azienda Ospedaliera San Giovanni, Torino, taly.

Gordon Cook (G)

Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.

Ma Victoria Mateos (MV)

University of Salamanca, Salamanca, Spain.

Hareth Nahi (H)

Karolinska Institutet, Stockholm, Sweden.

Hartmut Goldschmidt (H)

Universitätsklinikum Heidelberg, Heidelberg, Germany.

Meletios A Dimopoulos (MA)

University Athens School of Medicine, Athens, Greece.

Paulo Lucio (P)

Fundação Champalimaud, Lisbon, Portugal.

Joan Bladé (J)

Hospital Clinic de Barcelona, Barcelona, Spain.

Michel Delforge (M)

Department of Hematology, Catholic University of Leuven, Leuven, Belgium.

Roman Hajek (R)

University of Ostrava, Ostrava, Czech Republic.

Heinz Ludwig (H)

Wilhelminen Cancer Research Institute, Wilhelminen, Austria.

Thierry Facon (T)

University Hospital Hurriez, Lille, France.

Jesus F San Miguel (JFS)

University of Navarra, Navarra, Spain.

Hermann Einsele (H)

University of Wurzburg, Wurzburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Consensus › Chimeric antigen receptor T-cell therapy for...
questionsmedicales.fr › Régions géographiques › Europe › Chimeric antigen receptor T-cell therapy for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Chimeric antigen receptor T-cell therapy for...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Immunothérapie adoptive › Chimeric antigen receptor T-cell therapy for...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Chimeric antigen receptor T-cell therapy for...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Assurance de la qualité des soins de santé › Recommandations comme sujet › Guides de bonnes pratiques cliniques comme sujet › Chimeric antigen receptor T-cell therapy for...
questionsmedicales.fr › Organisations et économie des soins de santé › Organismes › Sociétés › Sociétés médicales › Chimeric antigen receptor T-cell therapy for...